Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clovanediol SCHEMBL24176172 | 1.00 | CYP3A4 (0.47) | CYP3A4F10MEN1KMT2APOLB | |
| Clovanediol SCHEMBL31338721 | 1.00 | CYP3A4 (0.47) | CYP3A4F10MEN1KMT2APOLB | |
| 2Beta-Methoxyclovan-9Alpha-Ol SCHEMBL4209224 | 0.83 | CYP3A4 (0.56) | CYP3A4F10MEN1KMT2APOLB | |
| 2Beta-Methoxyclovan-9Alpha-Ol SCHEMBL24176294 | 0.83 | CYP3A4 (0.56) | CYP3A4F10MEN1KMT2APOLB | |
| SCHEMBL24176577 | 0.78 | CYP3A4 (0.80) | CYP3A4F10MEN1KMT2APOLB | |
| SCHEMBL30105524 | 0.73 | F10 (0.41) | CYP3A4F10MEN1KMT2APOLB | |
| SCHEMBL4202172 | 0.65 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL24176299 | 0.64 | ALDH1A1 (0.53) | CYP3A4ALDH1A1 | |
| SCHEMBL15944367 | 0.64 | ALDH1A1 (0.53) | CYP3A4ALDH1A1 | |
| SCHEMBL29801778 | 0.64 | ALDH1A1 (0.53) | CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250113855-A1 | HYDRATING AND REHYDRATING COMPOSITOIN AND PRODUCT | IV THOUGHT PRODUCTS AND DESIGN CORP. | 2025-04-10 | — | — | US | claimed |
| WO-2022187973-A1 | DOSING REGIMENS OF PHARMACEUTICAL AND NUTRACEUTICAL MUSHROOM AND CANNABIS COMPOSITIONS AND THEIR USE TO TREAT CNS DISORDERS AND IMPROVE MENTAL HEALTH | ALLIED CORP. (CA) | 2022-09-15 | — | — | WO | claimed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4665318-A2 | THERAPEUTIC COMBINATIONS FOR INFLAMMATORY CONDITIONS AND DISORDERS | Native Code Bio, LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4583856-A2 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | Native Code Bio, LLC (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250113855-A1 | HYDRATING AND REHYDRATING COMPOSITOIN AND PRODUCT | IV THOUGHT PRODUCTS AND DESIGN CORP. | 2025-04-10 | — | — | US | disclosed |
| US-20250108082-A1 | THERAPEUTIC COMBINATIONS FOR INFLAMMATORY CONDITIONS AND DISORDERS | NATIVE CODE BIO, LLC | 2025-04-03 | — | — | US | disclosed |
| WO-2024234014-A1 | SUBLINGUAL SPRAY FORMULATIONS OF PSYCHEDELICS | SPIRITUS BIOSCIENCE, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024173954-A2 | THERAPEUTIC COMBINATIONS FOR INFLAMMATORY CONDITIONS AND DISORDERS | NATIVE CODE BIO, LLC (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024054688-A2 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO, LLC (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2022187973-A1 | DOSING REGIMENS OF PHARMACEUTICAL AND NUTRACEUTICAL MUSHROOM AND CANNABIS COMPOSITIONS AND THEIR USE TO TREAT CNS DISORDERS AND IMPROVE MENTAL HEALTH | ALLIED CORP. (CA) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108082-A1 | THERAPEUTIC COMBINATIONS FOR INFLAMMATORY CONDITIONS AND DISORDERS | HMBS, P2RY13, FDPS | CYP3A4 748/4885F10 1307/4885MEN1 2934/4885 |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | HMBS, SNCA, PYGB | CYP3A4 441/4885F10 2205/4885MEN1 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.